Effect of Citalopram on Health status, anxiety and depression in patients with chronic Obstructive pulmonary disease: a pilot study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN41544517

Enrollment

Registered

2008-04-21

Start date

2003-08-01

Completion date

Unknown

Last updated

2017-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease (COPD) Respiratory Pulmonary diseases

Interventions

Matching oral citalopram 20 mg and placebo, starting with half a tablet once per day for two weeks, then one tablet per day for the remaining weeks with monthly follow up for three months and a two we

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosis of COPD 2. Clinical diagnosis of anxiety or depression 3. Adults of either sex

Exclusion criteria

Exclusion criteria: 1. Severe ischaemic heart disease 2. On treatment for anxiety or depression 3. Terminal illness

Design outcomes

Primary

Measure	Time frame
Health-related quality of life, measured using St Georges Respiratory Questionnaire at baseline and 3 months	—

Secondary

Measure	Time frame
1. Depression and anxiety, measured using the Hospital Anxiety and Depression Score (HADS) at baseline and 3 months 2. Depression and anxiety, measured using the Depression in Medical Illness, a 10-item questionnaire (DM-10) at baseline and 3 months Additionally at baseline, 1, 2 and 3 months a structured side effect profile was checked.	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026